KYMERA THERAPEUTICS, INC. (KYMR) Operating Margin
- Operating margin · 12 months: Value -333.50%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -333.50% | Operating income / revenue. Period ending 2026-06-30. $-350.18M ÷ $105.00M × 100 ≈ -333.50% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -350.18M USD | Operating Income (Loss) |
| Revenue | 105.00M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 375.57M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-350.18M | $105.00M | (m) | $375.57M | (m) | -333.50% |
| 2026-03-31 | $-359.13M | $51.48M | (m) | $334.48M | (m) | -697.66% |
| 2025-12-31 | $-349.40M | $39.21M | (m) | $316.57M | (m) | -891.07% |
| 2025-09-30 | $-332.26M | $43.73M | (m) | $304.55M | (m) | -759.71% |
| 2025-06-30 | $-311.86M | $44.71M | (m) | $290.87M | (m) | -697.51% |
| 2025-03-31 | $-278.23M | $58.88M | (m) | $271.68M | (m) | -472.50% |
| 2024-12-31 | $-261.63M | $47.07M | (m) | $240.25M | (m) | -555.82% |
| 2024-09-30 | $-200.19M | $87.56M | (m) | $221.40M | (m) | -228.63% |
| 2024-06-30 | $-185.58M | $88.55M | (m) | $209.11M | (m) | -209.57% |
| 2024-03-31 | $-178.03M | $79.41M | (m) | $195.67M | (m) | -224.19% |
| 2023-12-31 | $-165.53M | $78.59M | (m) | $189.08M | (m) | -210.62% |
| 2023-09-30 | $-184.85M | $46.85M | (m) | $179.24M | (m) | -394.59% |
| 2023-06-30 | $-172.22M | $51.67M | (m) | $175.00M | (m) | -333.32% |
| 2023-03-31 | $-169.65M | $46.67M | (m) | $170.53M | (m) | -363.51% |
| 2022-12-31 | $-161.26M | $46.83M | (m) | $164.25M | (m) | -344.37% |
| 2022-09-30 | $-156.62M | $45.96M | (m) | $158.64M | (m) | -340.76% |
| 2022-06-30 | $-140.38M | $56.75M | (m) | $153.07M | (m) | -247.37% |
| 2022-03-31 | $-124.29M | $63.75M | (m) | $147.00M | (m) | -194.96% |
| 2021-12-31 | $-100.53M | $72.83M | (m) | $137.02M | (m) | -138.03% |
| 2021-09-30 | $-79.32M | $70.34M | (m) | $119.88M | (m) | -112.76% |
| 2021-06-30 | $-58.76M | $64.54M | (m) | $97.35M | (m) | -91.05% |
| 2021-03-31 | $-48.23M | $49.31M | (m) | $75.95M | (m) | -97.81% |
| 2020-12-31 | $-46.30M | $34.03M | (m) | $62.10M | (m) | -136.05% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-42.20M | $2.93M | (m) | $37.16M | (m) | -1438.48% |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |